Forty-four per cent: reading the nausea figure properly
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.
April 2024
Everything filed in April 2024, the month of Volume 1, Number 4. The issue itself — cover, editor’s letter and table of contents — is here.
STEP 4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
From the floor in Zhuhai: 8 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Why the customs shed is the least documented step in this trade
Degradation rates rise exponentially with temperature while an arithmetic mean adds linearly. Mean kinetic temperature is the weighting that reconciles the two, and it is…
The isotope pattern tells you the charge, and the charge tells you the mass
A peptide has a monoisotopic mass and an average mass, they differ by several daltons at this molecular size, and a certificate that does not say which it quotes cannot be…
What a 39% rise in coupling-reagent prices does to a 2 mg vial
Follow the resin, not the catalogue.
A shortage listing ends. 19 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The quiet end of Calder Vale Peptides of Skipton
A proper account of an operation that existed, and of what closing it cost.
Independent analysis puts a QST survodutide lot at 96.3%, against 95.4% on the certificate
A reminder that a purity figure is the output of a method, and that methods differ.
What the placebo arms of the withdrawal trials actually tell us
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
We split six vials four ways and posted them
Duplicate submissions under different names test within-laboratory repeatability, which is a different quantity from between-laboratory reproducibility.
What changed at WWB in April, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The 15-day notice: how a compounding wind-down works in Portugal
The document is four pages. Three of them are about dates.
The online reseller trading as Adamant Research Supply closes after 13 years
A proper account of an operation that existed, and of what closing it cost.
Germany caps dulaglutide prescribing to 24 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Manual reintegration is legitimate, and it should be declared
We work through a single chromatogram twice, under two integration conventions, and show where the difference comes from.
Why people actually stop, in the order they actually stop
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.
SURMOUNT-2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A shortage listing ends. 19 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The quiet end of the consolidator trading as Meridian Freight Partners
A proper account of an operation that existed, and of what closing it cost.
PeptideMeter result on a Chengdu exenatide lot lands 3.6 points below the supplier’s figure
The supplier has not disputed the finding. It has not explained the gap either.
Six words a verification badge would need to mean anything
A badge asserts that something was tested. It does not assert what, when, on whose sample, by what method, or whether the lot on sale is the lot that was tested.
Blind duplicates: what happens when a laboratory does not know it is being watched
Duplicate submissions under different names test within-laboratory repeatability, which is a different quantity from between-laboratory reproducibility.
SURPASS-3 was built to answer the stopping question, and it did
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
Inspectors cite the consolidator trading as Meridian Freight Partners over sterility assurance
The observation that closes a facility is rarely the dramatic one.
Mexico declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Reflux, early satiety, and the volume the stomach will accept
A single drug producing both constipation and diarrhoea looks contradictory until the motility data is read properly.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
A shortage listing ends. 24 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What a 40% rise in coupling-reagent prices does to a 2 mg vial
Follow the resin, not the catalogue.
What we asked twenty suppliers about stability data
We asked twenty companies three questions about stability data and print every answer, refusal and non-response.
Residual stomach content on endoscopy: the studies
A drug that delays gastric emptying complicates the assumption behind every fasting instruction in perioperative medicine. The professional bodies have moved twice on this…
From the floor in Zhuhai: 23 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
REWIND extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What the upper limit of normal for ALT should be, and why it is not
Asymptomatic pancreatic enzyme elevation is common on treatment and is not pancreatitis. The distinction is clinical, not biochemical.